Cargando…

Technical advances in NK cell-based cellular immunotherapy

Natural killer (NK) cells represent a promising future for tumor immunotherapy because of their unique biological functions and characteristics. This review focuses on technical advances in NK cell-based cellular immunotherapy and summarizes the developments of recent years in cell sources, genetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Fang, Wang, Wei, Chen, Minhua, Tian, Zhigang, Xiao, Weihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936239/
https://www.ncbi.nlm.nih.gov/pubmed/31908885
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0187
_version_ 1783483706033307648
author Fang, Fang
Wang, Wei
Chen, Minhua
Tian, Zhigang
Xiao, Weihua
author_facet Fang, Fang
Wang, Wei
Chen, Minhua
Tian, Zhigang
Xiao, Weihua
author_sort Fang, Fang
collection PubMed
description Natural killer (NK) cells represent a promising future for tumor immunotherapy because of their unique biological functions and characteristics. This review focuses on technical advances in NK cell-based cellular immunotherapy and summarizes the developments of recent years in cell sources, genetic modification, manufacturing systems, clinical programs, and outcomes. Future prospects and challenges in NK cell immunotherapy are also discussed, including off-the-shelf NK cell exploitation, automatic and closed manufacturing systems, cryopreservation, and therapies involving regulatory checkpoints.
format Online
Article
Text
id pubmed-6936239
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Chinese Anti-Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-69362392020-01-06 Technical advances in NK cell-based cellular immunotherapy Fang, Fang Wang, Wei Chen, Minhua Tian, Zhigang Xiao, Weihua Cancer Biol Med Review Natural killer (NK) cells represent a promising future for tumor immunotherapy because of their unique biological functions and characteristics. This review focuses on technical advances in NK cell-based cellular immunotherapy and summarizes the developments of recent years in cell sources, genetic modification, manufacturing systems, clinical programs, and outcomes. Future prospects and challenges in NK cell immunotherapy are also discussed, including off-the-shelf NK cell exploitation, automatic and closed manufacturing systems, cryopreservation, and therapies involving regulatory checkpoints. Chinese Anti-Cancer Association 2019-11 /pmc/articles/PMC6936239/ /pubmed/31908885 http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0187 Text en Copyright 2019 Cancer Biology & Medicine http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Review
Fang, Fang
Wang, Wei
Chen, Minhua
Tian, Zhigang
Xiao, Weihua
Technical advances in NK cell-based cellular immunotherapy
title Technical advances in NK cell-based cellular immunotherapy
title_full Technical advances in NK cell-based cellular immunotherapy
title_fullStr Technical advances in NK cell-based cellular immunotherapy
title_full_unstemmed Technical advances in NK cell-based cellular immunotherapy
title_short Technical advances in NK cell-based cellular immunotherapy
title_sort technical advances in nk cell-based cellular immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936239/
https://www.ncbi.nlm.nih.gov/pubmed/31908885
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0187
work_keys_str_mv AT fangfang technicaladvancesinnkcellbasedcellularimmunotherapy
AT wangwei technicaladvancesinnkcellbasedcellularimmunotherapy
AT chenminhua technicaladvancesinnkcellbasedcellularimmunotherapy
AT tianzhigang technicaladvancesinnkcellbasedcellularimmunotherapy
AT xiaoweihua technicaladvancesinnkcellbasedcellularimmunotherapy